BREAKING NEWS! CMS has announced new proposed mandated reporting on Diabetes Harm Measures, including severe Hypo and Hyperglycemic events. Learn More

Poised to address diabetes on a global scale, the company expands its intellectual property protections in the United States and abroad.

WALTHAM, MA — Glytec, the healthcare company behind a market-leading software solution for personalized diabetes therapy management, announces five new patent allowances for its eGlycemic Management System® (eGMS®), increasing the company’s portfolio to a total of 11 allowed or issued patents, with more than 50 pending.

Three of the new allowances were issued by the United States Patent and Trademark Office and two by the Israel Patent Office. The patents apply to proprietary systems and methods for intravenous and subcutaneous insulin therapies. They also address eGMS® integration with connected device systems — such as those which host and/or store blood glucose data — as well as enterprise health information systems, including electronic medical record systems (EMR); laboratory information systems (LIS); and admission, discharge and transfer systems (ADT).

“Technology innovation is one of Glytec’s core competencies, and it’s a significant investment for the company,” says Glytec’s Senior Vice President Research and Development, Robby Booth. “Our intellectual property protections, both here in the U.S. and abroad, speak to the unique and highly differentiated characteristics of our eGlycemic Management System®. Though, the improved clinical outcomes our clients achieve, and the associated cost savings, are the true testament of its worth.”

Glytec’s President and CEO, Bob Leonard, adds: “A recent case study published by one of our clients — a large regional academic medical center — shows annualized savings in excess of $9.7 million using eGMS® to achieve best practice and reduce incidence of hypoglycemia for hospitalized patients. In other studies, we’ve demonstrated how using eGMS® leads to a decrease in readmissions of 35-68% and a sustained drop in A1C levels of 2.6 percentage points for chronic care populations, both of which result in improved quality of care and great economic benefit, especially in light of alternative reimbursement models. eGMS® is an enabling solution of value to health systems, payers and patients alike.”

Statistics from myriad organizations, including American Diabetes Association, International Diabetes Federation, and World Health Organization, point to the fact that diabetes is a global epidemic. “The difficulties associated with diabetes therapy management, especially insulin dosing and titration, are universal,” says Leonard. “Our intensive pursuit of both domestic and international patents formidably positions Glytec for broad geographic growth.”

About Glytec

Founded in 2006, Glytec is the pioneer and leader in diabetes therapy management software, enabling healthcare organizations to standardize acute and chronic care, and achieve best practice for glucose control. The company’s comprehensive eGlycemic Management System® (eGMS®) has been proven to dramatically reduce drivers of cost and clinical variation, including hypoglycemia, readmissions, length of stay, complications and A1C levels. Its efficacy and safety have been validated by more than 55 research studies. eGMS® centers on an FDA-cleared insulin dosing solution that supports personalized intravenous and subcutaneous therapy for adult and pediatric populations. It integrates seamlessly with EMR and connected device systems for streamlined use across the entire continuum of care, including at-home, provider-directed care managed through telehealth, population health and other value-based programs. The company’s cloud-hosted software-as-a-service (SaaS) delivery model allows for rapid implementation and anytime, anywhere access. Glytec has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information, visit

View on Business Wire

Ready to take diabetes management to the next level?